List view / Grid view
Unleash the power of drug discovery with this FREE ebook supported by Sartorius! Explore the limitless potential of CRISPR applications and single cell sequencing for drug discovery. Access exclusive insights from industry leaders and stay ahead of the curve with the latest trends. Don't miss out on this opportunity to…
In this Antibodies In-depth Focus: Antibody fragment technology and avian IgY antibodies: a powerful combination; plus the challenges with antibody-based targeting of VEGF...
In this Assays In-Depth Focus: "Finding a cure for neglected tropical diseases with cell-based assays", plus "The relevance of homogeneous radiometric assays in modern drug discovery"...
Long term success for pharmaceutical businesses depends upon harnessing the best tools available to bring safe and effective medicines to market at a competitive price, and to be truly successful, for such drugs to be first in class.
17 March 2016 | By Drug Target Review
In this Drug Targets In-Depth Focus: "The alarming increase in antibioticresistant bacteria", plus "Computational methods for drug repositioning"; and "An overview of Alzheimer’s disease drug targets"...
Caroline Richards, Editor of Drug Target Review, asks Amrik Basran, Chief Scientific Officer at Avacta Life Sciences, to provide his views on Affimer® technology...
Microfluidic technology has great potential for complementing and, in some instances, replacing the use of animal models in the testing of medicines and in developing personalised treatments for cancer patients.
Biopharmaceuticals are highly complex protein drugs such as antibodies, cytokines and peptide hormones, which are used for a variety of indication areas, including immunology, neurology, metabolic diseases and cancer. These modern protein drugs may hinder progression of a disease, ease symptoms or assure – in the case of chronic diseases…
Non-alcoholic fatty liver disease (NAFLD), a consequence of sedentary life styles and high fat diets, has an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms within genes such as PNPLA3, TM6SF2, APOC3, NCAN and PPP1R3B correlate…
Brain tumours are complex cancer types, arising in many unique forms, each having varying survival rates and differing methods of treatment. Many brain tumours are difficult to clearly diagnose, leading to poor patient prognoses. Although they are mainly diagnosed by analysing morphological appearance, this does not closely correlate with the…
16 March 2016 | By Steve Bates, BioIndustry Association (BIA) Chief Executive
Here, Steve Bates, Chief Executive of the BioIndustry Association (BIA), makes a case for the UK remaining in the EU from the perspective of the life sciences sector...
8 March 2016 | By Edward D. Zanders, PharmaGuide Ltd, Cambridge, UK
Here, Edward D. Zanders explains his motivation behind writing ‘Human Drug Targets a Compendium for Pharmaceutical Discovery’ - a collection of current and potential drug targets mapped to human genes curated by the HGNC...
26 February 2016 | By Rodrigo Barnes, Chief Technology Officer at Aridhia
Here, Rodrigo Barnes, Chief Technology Officer at Aridhia, discusses how data analytics can add value to proof of concept trials...
23 February 2016 | By Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
Alzheimer’s disease (AD) is the most common form of dementia which typically occurs after the age of 65 and is characterised by progressive cognitive impairment...
Bioinformatics and computational techniques are now experiencing increased attention as a means of improving the costly and time-consuming drug development process...
